China Oncology ›› 2013, Vol. 23 ›› Issue (4): 267-272.doi: 10.3969/j.issn.1007-3969.2013.04.005

Previous Articles     Next Articles

Association between XPC and XRCC1 polymorphism and prognosis of primary hepatocellular carcinoma after radical resection

PAN Dong-xiang1, QIU Xiao-qiang1,2, ZENG Xiao-yun1, LIU Shun1, BAI Hua1, TAN Chao1, HUANG Hui1   

  1. 1.Department of Epidemiology and Health Statistics, School of Public Health, Guangxi Medical University, Nanning Guangxi 530021, China; 2. School of Public Health, Guilin Medical University, Guilin Guangxi 541004, China
  • Online:2013-04-25 Published:2014-11-19
  • Contact: QIU Xiao-qiang E-mail: xqqiu9999@sina.com

Abstract:

Background and purpose: The literature suggests, XPC and XRCC1 gene polymorphisms were associated with tumors prognosis in recent years, but fewer studies have reported their association with liver cancer prognosis. This study aimed to investigate the association between single nucleotide polymorphism of XPC939, XRCC1-399 and prognosis of hepatocellular carcinoma (HCC) after radical resection. Methods: The blood of DNA and the data of clinical pathology, prognosis of survival of HCC patients who underwent radical resection and were hospitalized at Guangxi Medical University First Affiliated Hospital between Feb. 2007 and Oct. 2008 were analyzed, 143 cases with complete follow-up data were respectively analyzed. XPC939, XRCC1-399 genotypes were tested by TaqMan-MGB real-time fluorescence quantitative polymerase chain reaction (RT-PCR) technology. Kaplan-Meier method was used to analyze prognosis, log-rank test was used to compare between groups, and the Cox proportional hazards model was used for multivariate analysis. Results: The 1-, 2- and 3-year survival rates were 81.8%, 76.2%, 67.1%, respectively. Median progression-free survival time was 27 months. Survival analysis showed that patients carrying allelic genotype of XPC939 C(AC + CC) had a longer median progression-free survival time (32 months) than the those carrying XPC939 A alleles (AA) genotype (16 months) (χ2=4.320, P<0.05). Tumor diameter stratified analysis showed that overall survival of patients carrying genotype of XRCC1-399 GG was higher than those carrying XRCC1-399 GA + AA genotype (χ2=4.105, P<0.05). Cox multivariate analysis did not show that XRCC1-399 was independently associated with HCC prognosis. Conclusion: Of all HCC patients after radical resection, there is no association between XPC939, XRCC1-399 polymorphism and clinical features, but XPC939 polymorphism is associated with progressionfree survival and XRCC1-399 polymorphism may have a certain influence on the long-term prognosis of HCC patients after radical resection.

Key words: Hepatocellular carcinoma, XPC939 and XRCC1-399, Single nucleotide polymorphisms, Survival analysis